Results of Phase Iii Bravo Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment
نویسنده
چکیده
• Primary endpoint of reducing annualized relapse rate was not statistically achieved • Following a standard adjustment, in accordance with a pre-defined sensitivity analysis, laquinimod significantly reduced the annualized relapse rate (p=0.026) • Laquinimod also demonstrated significant reductions in both brain volume loss and the risk of disability progression, while maintaining a favorable safety and tolerability profile • Regulatory submissions are planned in the U.S. and EU • Teva to host conference call to discuss study results on August 1, 8:30 a.m. EDT
منابع مشابه
Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review
INTRODUCTION Multiple sclerosis (MS) is considered an autoimmune disease with inflammatory and neurodegenerative underlying processes that affect the central nervous system. The available disease-modifying therapies (DMTs) approved to treat MS have only shown partial benefit in controlling the disease progression, primarily impeding its inflammatory component, while the parenteral administratio...
متن کاملNew approaches in the management of multiple sclerosis
Multiple sclerosis (MS) is a central nervous system chronic inflammatory disease that is characterized by an extensive and complex immune response. Scientific advances have occurred in immunology, pathophysiology, and diagnostic and clinical assessment tools, and recent discovery of unique therapeutic targets has spurred numerous Phase II and Phase III clinical trials. Reductions in MS relapse ...
متن کاملLaquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagree
BACKGROUND The results of two randomized phase 3 trials that investigated the use of laquinimod in patients with relapsing-remitting multiple sclerosis were analyzed using a propensity score model. METHODS The propensity score in each study was defined as the probability of an individual patient being assigned to either the laquinimod or placebo study arm. The analysis included two main stage...
متن کاملLaquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis
Laquinimod is a novel oral drug that is currently being evaluated for the treatment of relapsing-remitting multiple sclerosis (RRMS). Although the mode of action of laquinimod remains to be fully elucidated, current knowledge indicates that laquinimod exerts beneficial activities both on the peripheral immune system and within the central nervous system (CNS). The immunomodulatory properties ha...
متن کاملEmerging multiple sclerosis oral therapies.
Currently, patients suffering from multiple sclerosis (MS), a chronic demyelinating disorder of the CNS, must be injected with medication to provide modest relief for their symptoms. Five orally available therapies are being evaluated in phase II/III clinical trials. If these therapies prove safe and tolerable, oral compounds may improve patient endorsement and compliance. Fingolimod, a novel i...
متن کامل